{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:40:33Z","timestamp":1789609233880,"version":"build-2803163510"},"reference-count":42,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2019,4,29]],"date-time":"2019-04-29T00:00:00Z","timestamp":1556496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,8,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Toxic epidermal necrolysis (TEN) is a potentially life-threatening, exfoliative disease. It is described as idiosyncratic, severe, skin reaction to drugs. With Stevens\u2013Johnson\u2019s Syndrome, it presents as a continuum of a disease being categorized relating to the percentage of affected skin. Without any multicenter trials comparing TEN treatment modalities, there is dearth of strong evidence-based guidelines of care. Total plasma exchange with intravenous immunoglobulin (IVIG) is one among plethora of possible treatment strategies. In our 10-year experience, we have observed 21 patients admitted to our burns center due to TEN. All of them were placed under intensive care with daily plasmapheresis (TPE) and IVIG. We have observed 52% mortality, with observed severe concomitant diseases in every patient in nonsurvivor group (average Acute Physiology and Chronic Health Evaluation II score at admission: 31.5%). We consider that TPE with IVIG might be of use in selected group of patients with TEN without any severe comorbidities. However, further multicenter trials are needed because in some cases it may raise mortality.<\/jats:p>","DOI":"10.1093\/jbcr\/irz073","type":"journal-article","created":{"date-parts":[[2019,4,29]],"date-time":"2019-04-29T03:23:24Z","timestamp":1556508204000},"page":"652-657","source":"Crossref","is-referenced-by-count":14,"title":["Toxic Epidermal Necrolysis Therapy with TPE and IVIG\u201410 Years of Experience of the Burns Treatment Center"],"prefix":"10.1093","volume":"40","author":[{"given":"Andrzej","family":"Krajewski","sequence":"first","affiliation":[{"name":"West Pomeranian Burns and Plastic Surgery Center, Gryfice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4710-1282","authenticated-orcid":false,"given":"Maciej Jan","family":"Mazurek","sequence":"additional","affiliation":[{"name":"West Pomeranian Burns and Plastic Surgery Center, Gryfice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elzbieta","family":"Mlynska-Krajewska","sequence":"additional","affiliation":[{"name":"West Pomeranian Burns and Plastic Surgery Center, Gryfice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Piorun","sequence":"additional","affiliation":[{"name":"West Pomeranian Burns and Plastic Surgery Center, Gryfice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateusz","family":"Knakiewicz","sequence":"additional","affiliation":[{"name":"West Pomeranian Burns and Plastic Surgery Center, Gryfice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Markowska","sequence":"additional","affiliation":[{"name":"West Pomeranian Burns and Plastic Surgery Center, Gryfice, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,4,29]]},"reference":[{"key":"2019081416351075600_CIT0001","first-page":"231","article-title":"L\u2019erythrodermie bulleuses avec epidermolyse","volume":"37","author":"Debre","year":"1939","journal-title":"Bull Soc Pediat"},{"key":"2019081416351075600_CIT0002","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1365-2133.1956.tb12766.x","article-title":"Toxic epidermal necrolysis: an eruption resembling scalding of the skin","volume":"68","author":"Lyell","year":"1956","journal-title":"Br J Dermatol"},{"key":"2019081416351075600_CIT0003","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13430","article-title":"Severe cutaneous adverse drug reactions","author":"Chung","year":"2016","journal-title":"J Dermatol"},{"key":"2019081416351075600_CIT0004","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S1085-5629(96)80039-3","article-title":"Advances in toxic epidermal necrolysis","volume":"15","author":"Revuz","year":"1996","journal-title":"Semin Cutan Med Surg"},{"key":"2019081416351075600_CIT0005","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/S1085-5629(96)80036-8","article-title":"Epidemiology of drug-induced severe skin reactions","volume":"15","author":"Mockenhaupt","year":"1996","journal-title":"Semin Cutan Med Surg"},{"key":"2019081416351075600_CIT0006","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1056\/NEJM199512143332404","article-title":"Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis","volume":"333","author":"Roujeau","year":"1995","journal-title":"N Engl J Med"},{"key":"2019081416351075600_CIT0007","doi-asserted-by":"crossref","first-page":"e297","DOI":"10.1542\/peds.2008-1923","article-title":"Medications as risk factors of Stevens-Johnson syndrome and toxic epidermal necrolysis in children: a pooled analysis","volume":"123","author":"Levi","year":"2009","journal-title":"Pediatrics"},{"key":"2019081416351075600_CIT0008","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.amjmed.2016.03.022","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis: an analysis of triggers and implications for improving prevention","volume":"129","author":"Miliszewski","year":"2016","journal-title":"Am J Med"},{"key":"2019081416351075600_CIT0009","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/BCR.0b013e31815f3865","article-title":"SCORTEN accurately predicts mortality among toxic epidermal necrolysis patients treated in a burn center","volume":"29","author":"Cartotto","year":"2008","journal-title":"J Burn Care Res"},{"key":"2019081416351075600_CIT0010","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1046\/j.1523-1747.2000.00061.x","article-title":"SCORTEN: a severity-of-illness score for toxic epidermal necrolysis","volume":"115","author":"Bastuji-Garin","year":"2000","journal-title":"J Invest Dermatol"},{"key":"2019081416351075600_CIT0011","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1001\/jama.2014.10783","article-title":"Recurrence of Stevens-Johnson syndrome and toxic epidermal necrolysis\u2013reply","volume":"312","author":"Finkelstein","year":"2014","journal-title":"JAMA"},{"key":"2019081416351075600_CIT0012","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1001\/jama.2014.10777","article-title":"Recurrence of Stevens-Johnson syndrome and toxic epidermal necrolysis","volume":"312","author":"Stern","year":"2014","journal-title":"JAMA"},{"issue":"4","key":"2019081416351075600_CIT0013","doi-asserted-by":"publisher","first-page":"CD001435","DOI":"10.1002\/14651858.CD001435","article-title":"Interventions for toxic epidermal necrolysis","author":"Majumdar","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"key":"2019081416351075600_CIT0014","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1177\/039139889101401006","article-title":"Plasma exchange (PE) treatment in drug-induced toxic epidermal necrolysis (TEN)","volume":"14","author":"Sakellariou","year":"1991","journal-title":"Int J Artif Organs"},{"key":"2019081416351075600_CIT0015","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1365-4362.1989.tb02502.x","article-title":"Drug-induced toxic epidermal necrolysis treated with cyclosporin","volume":"28","author":"Renfro","year":"1989","journal-title":"Int J Dermatol"},{"key":"2019081416351075600_CIT0016","first-page":"259","article-title":"Lyell\u2019s syndrome: treatment by plasma exchange","volume":"5","author":"Gerard","year":"1984","journal-title":"Plasma Ther Transfus Technol"},{"key":"2019081416351075600_CIT0017","doi-asserted-by":"crossref","first-page":"e119","DOI":"10.1016\/j.bjps.2016.01.034","article-title":"UK guidelines for the management of Stevens-Johnson syndrome\/toxic epidermal necrolysis in adults 2016","volume":"69","author":"Creamer","year":"2016","journal-title":"J Plast Reconstr Aesthet Surg"},{"key":"2019081416351075600_CIT0018","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.17841","article-title":"British Association of Dermatologists guidelines for the management of Stevens-Johnson syndrome\/toxic epidermal necrolysis in children and young people 2018","author":"McPherson","year":"2019","journal-title":"Br J Dermatol"},{"key":"2019081416351075600_CIT0019","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1001\/jamadermatol.2017.0160","article-title":"Stevens-Johnson syndrome and toxic epidermal necrolysis standard reporting and evaluation guidelines: results of a National Institutes of Health Working Group","volume":"153","author":"Maverakis","year":"2017","journal-title":"JAMA Dermatol"},{"key":"2019081416351075600_CIT0020","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/j.1346-8138.2010.01154.x","article-title":"Efficacy of plasmapheresis for the treatment of severe toxic epidermal necrolysis: is cytokine expression analysis useful in predicting its therapeutic efficacy?","volume":"38","author":"Narita","year":"2011","journal-title":"J Dermatol"},{"key":"2019081416351075600_CIT0021","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/j.1744-9987.2008.00609.x","article-title":"Status of plasmapheresis for the treatment of toxic epidermal necrolysis in Japan","volume":"12","author":"Yamada","year":"2008","journal-title":"Ther Apher Dial"},{"key":"2019081416351075600_CIT0022","doi-asserted-by":"crossref","first-page":"e1221","DOI":"10.1097\/GOX.0000000000001221","article-title":"Management of toxic epidermal necrolysis with plasmapheresis and cyclosporine a: our 10 years\u2019 experience","volume":"5","author":"Giudice","year":"2017","journal-title":"Plast Reconstr Surg Glob Open"},{"key":"2019081416351075600_CIT0023","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2147\/CLEP.S133624","article-title":"Charlson comorbidity index derived from chart review or administrative data: agreement and prediction of mortality in intensive care patients","volume":"9","author":"Stavem","year":"2017","journal-title":"Clin Epidemiol"},{"key":"2019081416351075600_CIT0024","doi-asserted-by":"crossref","first-page":"203","DOI":"10.2147\/CLEP.S20247","article-title":"Comparison of Charlson comorbidity index with SAPS and APACHE scores for prediction of mortality following intensive care","volume":"3","author":"Christensen","year":"2011","journal-title":"Clin Epidemiol"},{"key":"2019081416351075600_CIT0025","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/1750-1172-5-39","article-title":"Toxic epidermal necrolysis and Stevens-Johnson syndrome","volume":"5","author":"Harr","year":"2010","journal-title":"Orphanet J Rare Dis"},{"key":"2019081416351075600_CIT0026","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.alit.2016.06.001","article-title":"A review of toxic epidermal necrolysis management in Japan","volume":"66","author":"Kinoshita","year":"2016","journal-title":"Allergol Int"},{"key":"2019081416351075600_CIT0027","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1097\/00003246-200211000-00029","article-title":"Recurrent fatal drug-induced toxic epidermal necrolysis (Lyell\u2019s syndrome) after putative beta-lactam cross-reactivity: case report and scrutiny of antibiotic imputability","volume":"30","author":"Paquet","year":"2002","journal-title":"Crit Care Med"},{"key":"2019081416351075600_CIT0028","first-page":"92","article-title":"[Recurrent Lyell\u2019s syndrome with secondary thrombocytopenia]","volume":"69","author":"Epishin","year":"1991","journal-title":"Klin Med (Mosk)"},{"key":"2019081416351075600_CIT0029","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1001\/jama.2014.839","article-title":"Recurrence and mortality following severe cutaneous adverse reactions","volume":"311","author":"Finkelstein","year":"2014","journal-title":"JAMA"},{"key":"2019081416351075600_CIT0030","unstructured":"Jeffrey\n              P\n            , CallenM. Frequency of recurrence of Stevens-Johnson syndrome or toxic epidermal necrolysis: Massachusetts Medical Society; 2014; available from http:\/\/www.jwatch.org\/na34825\/2014\/06\/04\/frequency-recurrence-stevens-johnson-syndrome-or-toxic; accessed 1 Dec. 2018."},{"key":"2019081416351075600_CIT0031","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.burns.2017.09.015","article-title":"Improving mortality outcomes of Stevens Johnson syndrome\/toxic epidermal necrolysis: a regional burns centre experience","volume":"44","author":"Nizamoglu","year":"2018","journal-title":"Burns"},{"key":"2019081416351075600_CIT0032","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2018.5605","article-title":"Development and validation of a risk prediction model for in-hospital mortality among patients with Stevens-Johnson syndrome\/toxic epidermal necrolysis-ABCD-10","author":"Noe","year":"2019","journal-title":"JAMA Dermatol"},{"key":"2019081416351075600_CIT0033","doi-asserted-by":"crossref","first-page":"15","DOI":"10.12688\/wellcomeopenres.13940.2","article-title":"The Liverpool Care Pathway for the Dying Patient: a critical analysis of its rise, demise and legacy in England","volume":"3","author":"Seymour","year":"2018","journal-title":"Wellcome Open Res"},{"key":"2019081416351075600_CIT0034","doi-asserted-by":"crossref","first-page":"250","DOI":"10.12968\/bjcn.2014.19.5.250","article-title":"End-of-life care after the Liverpool Care Pathway","volume":"19","author":"Middleton-Green","year":"2014","journal-title":"Br J Community Nurs"},{"key":"2019081416351075600_CIT0035","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1177\/1471301217729532","article-title":"The challenge pathway: a mixed methods evaluation of an innovative care model for the palliative and end-of-life care of people with dementia (Innovative practice)","volume":"17","author":"Harrop","year":"2018","journal-title":"Dementia (London)"},{"key":"2019081416351075600_CIT0036","doi-asserted-by":"publisher","first-page":"e7","DOI":"10.1016\/j.apnr.2015.05.014","article-title":"Resuscitation versus end-of-life care: exploring the obstacles and supportive behaviors to providing end-of-life care as perceived by emergency nurses after implementing the end-of-life care pathway","volume":"29","author":"Ka-Ming Ho","year":"2016","journal-title":"Appl Nurs Res"},{"key":"2019081416351075600_CIT0037","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1097\/00004630-200203000-00004","article-title":"A multicenter review of toxic epidermal necrolysis treated in U.S. burn centers at the end of the twentieth century","volume":"23","author":"Palmieri","year":"2002","journal-title":"J Burn Care Rehabil"},{"key":"2019081416351075600_CIT0038","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.burns.2017.10.022","article-title":"Treatment of toxic epidermal necrolysis by a multidisciplinary team. A review of literature and treatment results","volume":"44","author":"Papp","year":"2018","journal-title":"Burns"},{"key":"2019081416351075600_CIT0039","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1001\/archderm.139.1.33","article-title":"Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression","volume":"139","author":"Bachot","year":"2003","journal-title":"Arch Dermatol"},{"key":"2019081416351075600_CIT0040","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/01.BCR.0000105096.93526.27","article-title":"Toxic epidermal necrolysis: does immunoglobulin make a difference?","volume":"25","author":"Brown","year":"2004","journal-title":"J Burn Care Rehabil"},{"key":"2019081416351075600_CIT0041","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/j.burns.2018.03.006","article-title":"Toxic epidermal necrolysis data from the CELESTE multinational registry. Part II: specific systemic and local risk factors for the development of infectious complications","volume":"44","author":"Lipov\u00fd","year":"2018","journal-title":"Burns"},{"key":"2019081416351075600_CIT0042","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/j.burns.2018.01.019","article-title":"Toxic epidermal necrolysis data from the CELESTE multinational registry. Part I: epidemiology and general microbiological characteristics","volume":"44","author":"Lipov\u00fd","year":"2018","journal-title":"Burns"}],"container-title":["Journal of Burn Care &amp; Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jbcr\/advance-article-pdf\/doi\/10.1093\/jbcr\/irz073\/28672795\/irz073.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jbcr\/article-pdf\/40\/5\/652\/29163670\/irz073.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,16]],"date-time":"2019-08-16T12:07:53Z","timestamp":1565957273000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jbcr\/article\/40\/5\/652\/5481218"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,29]]},"references-count":42,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2019,4,29]]},"published-print":{"date-parts":[[2019,8,14]]}},"URL":"https:\/\/doi.org\/10.1093\/jbcr\/irz073","relation":{},"ISSN":["1559-047X","1559-0488"],"issn-type":[{"value":"1559-047X","type":"print"},{"value":"1559-0488","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,9]]},"published":{"date-parts":[[2019,4,29]]}}}